October 21, 2025
Article
The addition of postsurgical Verzenio to endocrine therapy provided a benefit in HR–positive, HER2-negative breast cancer.
October 20, 2025
Camrelizumab plus famitinib extended progression-free survival to 11.1 months versus 7.5 months with chemotherapy in recurrent or metastatic cervical cancer.
October 19, 2025
Platinum chemo with Imfinzi, Avastin, and Lynparza improved progression-free survival versus chemo and Avastin but did not extend overall survival.
October 18, 2025
Enhertu led to a 53% reduction in the risk of invasive disease or death versus Kadcyla in some patients with high-risk, HER2-positive breast cancer.
Cancer From A Patient’s Point of View
Hernexeos Effective in HER2-Mutated NSCLC
Anemia Management in Myelofibrosis: Survival and Quality of Life
Simple Ways for Patients With Cancer to Start Exercising